Demeter Judit, Poros Anna, Bödör Csaba, Horváth Laura, Masszi Tamás
I. Belgyógyászati Klinika, Semmelweis Egyetem, Általános Orvostudományi Kar Budapest, Korányi Sándor u. 2/a, 1083.
Magyar Honvédség Egészségügyi Központ Budapest.
Orv Hetil. 2016 Sep;157(37):1459-68. doi: 10.1556/650.2016.30521.
Chronic myelogenous leukemia is a clonal myeloproliferative neoplasm caused by reciprocal translocation involving chromosomes 9 and 22 resulting in the expression of a constitutively activated BCR-ABL1 tyrosine kinase that leads to the malignant transformation of the hematopoietic stem cells. The condition was previously known as a relentlessly progressive disease, but the treatment was revolutionalized by the efficacy of tyrosine kinase inhibitors. Therapeutic success is thus currently determined by the depth of molecular response achieved on therapy. Multiple tyrosine kinase agents are available even for the first line treatment. This guideline summarizes current focal points of the treatment of chronic myelogenous leukemia specific to Hungary and provides definitions for optimal molecular responses in this condition. Orv. Hetil., 2016, 157(37), 1459-1468.
慢性粒细胞白血病是一种克隆性骨髓增殖性肿瘤,由涉及9号和22号染色体的相互易位引起,导致组成型激活的BCR-ABL1酪氨酸激酶表达,进而导致造血干细胞发生恶性转化。该疾病以前被认为是一种进展迅速的疾病,但酪氨酸激酶抑制剂的疗效彻底改变了治疗方法。因此,目前治疗成功与否取决于治疗后所达到的分子反应深度。即使是一线治疗也有多种酪氨酸激酶药物可供选择。本指南总结了匈牙利慢性粒细胞白血病治疗的当前重点,并给出了这种情况下最佳分子反应的定义。《匈牙利医学周报》,2016年,157(37),1459 - 1468。